RAS - 医索

找到约 125 条结果

全球首个国产KRAS抑制剂获批上市，开启精准医疗新纪元

8月21日，据NMPA官网公示，信达生物/劲方医药合作开发的KRAS G12C抑制剂氟泽雷塞片获批上市，用于治疗至少接受过一种系统性治疗的KRAS G12C突变型晚期非小细胞肺癌（NSCLC）成人患者。这不仅是首个在国内获批的 KR.....

学术资讯 - 热点资讯

Trastuzumab and pertuzumab in combination witheribulin mesylate or a taxane as first-linechemotherapeutic treatment for HER2-positive, locallyadvanced or metastatic breast cancer results of amulti

医客学院 - 会议报告集

Primary results from PATRICIA Cohort c (SOLTI-1303)a randomized phase ll study evaluating palbociclib withtrastuzumab and endocrine therapy in pretreated HER2.positive and PAM50 luminal advanced b

医客学院 - 会议报告集

Updated results from the Phase 1b2 HERKULES-3 studyERAS-007 plus encorafenib and cetuximab (Ec)inpatients (pts)with EC-naive metastatic BRAF V600Ecolorectal cancer (CRC)

医客学院 - 会议报告集

Overall survival (oS) of phase 3 CodeBreak 300 study ofsotorasib plus panitumumab (soto pani) versus investigator'schoice of therapy for KRAS G12c-mutated metastatic colorectacancer (mCRc)

医客学院 - 会议报告集

MOUNTAINEER FINAL RESULTS OF APHASE 2 STUDY OF TUCATINIB ANDTRASTUZUMAB FOR HER2-POSITIVEMETASTATIC CRC

医客学院 - 会议报告集

FUFA maintenance therapy with or withoutpanitumumab(pmab)in RAS wild-type metastaticcolorectal cancer(mCRC)(PanaMa, AlO KRK 0212)Updated efficacy analyses

医客学院 - 会议报告集

RAS野生型转移性结直肠癌抗表皮生长因子受体单抗维持治疗中国专家共识(2024版)

医客学院 - 指南共识

再次发力！龙年曹雪涛团队连发2篇PNAS及Nature子刊

临床研究协调代谢重编程和表观遗传重塑是调节T细胞功能和分化的关键。然而，表观遗传修饰如何通过代谢重编程控制Th17/Treg细胞平衡仍然不清楚。2024年2月15日，中国医学科学院/北京协和医学院/海军军医大学/南开大学曹雪涛团队在PNAS在线.....
学术资讯 - 临床研究

KRAS，HER2 and the emergence ofmore actionable mutations (TINA)

医客学院 - 会议报告集

首页

上一页

1
2
3
4
5
...
12
13

下一页

尾页

今日实时热搜

医学论文专业中译英服务（含母语化润色）

病例集出版物

国家科学自然基金标书指导服务

全球首个国产KRAS抑制剂获批上市，开启精准医疗新纪元

Trastuzumab and pertuzumab in combination witheribulin mesylate or a taxane as first-linechemotherapeutic treatment for HER2-positive, locallyadvanced or metastatic breast cancer results of amulti

Primary results from PATRICIA Cohort c (SOLTI-1303)a randomized phase ll study evaluating palbociclib withtrastuzumab and endocrine therapy in pretreated HER2.positive and PAM50 luminal advanced b

Updated results from the Phase 1b2 HERKULES-3 studyERAS-007 plus encorafenib and cetuximab (Ec)inpatients (pts)with EC-naive metastatic BRAF V600Ecolorectal cancer (CRC)

Overall survival (oS) of phase 3 CodeBreak 300 study ofsotorasib plus panitumumab (soto pani) versus investigator'schoice of therapy for KRAS G12c-mutated metastatic colorectacancer (mCRc)

MOUNTAINEER FINAL RESULTS OF APHASE 2 STUDY OF TUCATINIB ANDTRASTUZUMAB FOR HER2-POSITIVEMETASTATIC CRC

FUFA maintenance therapy with or withoutpanitumumab(pmab)in RAS wild-type metastaticcolorectal cancer(mCRC)(PanaMa, AlO KRK 0212)Updated efficacy analyses

RAS野生型转移性结直肠癌抗表皮生长因子受体单抗维持治疗中国专家共识(2024版)

再次发力！龙年曹雪涛团队连发2篇PNAS及Nature子刊

KRAS，HER2 and the emergence ofmore actionable mutations (TINA)